Streetbeat News

Revenues

BACHY

Bank Of China reported Q3 earnings per share of $0.66, unchanged from last year, with sales increasing by 7.58% to $22.48 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:09 am

DAY

Dayforce has raised its fiscal year 2024 revenue guidance to a range of $1.747 billion to $1.752 billion, up from the previous range of $1.736 billion to $1.746 billion. This new guidance surpasses the estimated $1.742 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:08 am

OSK

Oshkosh Corporation has updated its financial outlook for FY24, projecting an adjusted EPS of $11.35, slightly below the estimate of $11.40, but within the prior range of $10.45-$11.75. The company also forecasts revenues of $10.6 billion, slightly above the estimate of $10.51 billion, but below the prior view of $10.7 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:08 am

EXTR

Extreme Networks reported its Q1 2025 financial results, with adjusted EPS of $0.17, surpassing the estimate of $0.12. The company's sales reached $269.204 million, exceeding the expected $260.547 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:08 am

NBIX

Neurocrine Biosciences has increased its fiscal year 2024 net product revenue outlook for valbenazine to a range of $2.30 billion to $2.32 billion.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:07 am

DAY

Dayforce has released its Q4 2024 financial guidance, projecting revenue between $452 million and $457 million, which is below the market estimate of $458 million. The company also expects adjusted EBITDA to range from $120 million to $135 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:06 am

CHEF

The Chefs' Warehouse reported its Q3 2024 financial results, with adjusted EPS of $0.36 beating the estimate of $0.34. However, sales of $931.452 million missed the expected $936.292 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:06 am

BPMC

Blueprint Medicines has raised its 2024 net product revenue guidance for Ayvakit to $475M-$480M, up from $435M-$450M, due to growth in patient therapy and strong performance outside the U.S. The company expects reduced operating expenses and cash burn in 2024, aiming for a self-sustainable financial profile.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:05 am

NBIX

Neurocrine Biosciences reported Q3 2024 earnings of $1.81 per share, surpassing the $1.51 estimate, and sales of $622.1M, exceeding the $600.628M estimate. This marks a significant year-over-year growth in both earnings and sales.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:05 am

UE

Urban Edge Properties (NYSE:UE) reported Q3 earnings of $0.35 per share, surpassing the $0.33 estimate and showing a 9.37% increase from last year. Sales reached $112.43M, slightly above the $112.26M estimate, marking a 10.40% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:05 am